Research programme: myostatin - SYN X Pharma

Drug Profile

Research programme: myostatin - SYN X Pharma

Alternative Names: Myostatin research programme - SYN X Pharma

Latest Information Update: 15 May 2007

Price : $50

At a glance

  • Originator Universite de Liege
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Muscular atrophy; Myocardial infarction

Most Recent Events

  • 07 Aug 2006 No development reported - Preclinical for Muscle wasting in Belgium (unspecified route)
  • 07 Aug 2006 No development reported - Preclinical for Myocardial infarction in Belgium (unspecified route)
  • 07 May 2004 SYN X Pharma has been acquired by Nanogen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top